Preanalytical quality control program – an overview of results (2001–2005 summary)
-
Ma Jesús Alsina
Abstract
Background: Preanalytical variables, such as sample collection, handling, transport, and storage, may affect patient results. The number of errors in the preanalytical phase may decrease by following standardized procedures.
Methods: A retrospective analysis (2001–2005) of results obtained through the Spanish Society of Clinical Chemistry and Molecular Pathology Quality Assessment Program for the Preanalytical Phase has been carried out to summarize data regarding the main factors affecting the preanalytical phase quality. In such a program, participants are asked to register rejections and causes for rejection of routine or stat samples usually and locally collected at their laboratories.
Results: Results discussed refer to 105 laboratories. Of the 4,715,132 tubes expected to be received during the data collection period among participating laboratories and according to determinations included by clinicians in the request form, 32,977 (0.699%) offered a cause for rejection. Whole blood-EDTA samples and serum samples accounted for 75.6% of all samples collected among laboratories, although they only corresponded to 55.8% of all registered rejections. In total, 81% of rejections arose as a result of the following reasons: “specimen not received” (37.5%), “hemolysis” (29.3%), and “clotted sample” (14.4%). Moreover, plasma-citrate-erythrocyte sedimentation rate exhibited the highest percentage of rejection (1.473%), whereas the lowest rate corresponded to whole blood-EDTA (0.381%).
Conclusions: Overall percentage of rejection is similar to previously published data. As some of the included variables have turned out to be irrelevant, the program has been simplified from the year 2006 onwards.
Clin Chem Lab Med 2008;46:849–54.
©2008 by Walter de Gruyter Berlin New York
Artikel in diesem Heft
- Reviews
- The STANISLAS Cohort: a 10-year follow-up of supposed healthy families. Gene-environment interactions, reference values and evaluation of biomarkers in prevention of cardiovascular diseases
- Cardiovascular biomarkers: increasing impact of laboratory medicine in cardiology practice
- Haemolysis: an overview of the leading cause of unsuitable specimens in clinical laboratories
- Cardiovascular Diseases
- APOA5 Ala315>Val, identified in patients with severe hypertriglyceridemia, is a common mutation with no major effects on plasma lipid levels
- Gender-modulated impact of apolipoprotein A5 gene (APOA5) −1131T>C and c.56C>G polymorphisms on lipids, dyslipidemia and metabolic syndrome in Turkish adults
- Oxidative stress markers, C-reactive protein and heat shock protein 70 levels in subjects with metabolic syndrome
- Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing
- Distribution of plasma cardiac troponin I values in healthy subjects: pathophysiological considerations
- High-density lipoprotein cholesterol and paraoxonase 1 (PON1) genetics and serum PON1 activity in prepubertal children in Spain
- Genetics and Molecular Diagnostics
- Polymorphisms of CYP17A1, CYP19, and androgen in Brazilian women with uterine leiomyomas
- A novel MEN1 frameshift germline mutation in two Italian monozygotic twins
- The silent hemoglobin α chain variant Hb Riccarton [α51(CE9)Gly→Ser] may affect HbA1c determination on the HLC-723 G7 analyzer
- General Clinical Chemistry and Laboratory Medicine
- Urinary fructose-1,6-bisphosphatase activity as a marker of the damage to the renal proximal tubules in children with idiopathic nephrotic syndrome
- Antioxidant defense capacity in scleroderma patients
- Correction of ventricular cerebrospinal fluid (CSF) samples for blood content does not increase sensitivity and specificity for the detection of CSF infection
- Validation and Outcome Studies
- Preanalytical quality control program – an overview of results (2001–2005 summary)
- A laboratory-based risk score for medical intensive care patients
- Analytical performance evaluation of the Cobas 6000 analyzer – special emphasis on trueness verification
- Letters to the Editor
- Quality planning and analytical quality requirements derived from biology
- Importance of sample size in hospital point-of-care glucose measurements
- Reliability of M protein quantification: comparison of two peak integration methods on Capillarys 2
- What's in a name? Standardization of HbA1c
- Serum paraoxonase 1 activities and homocysteinemia in hemodialysis patients
Artikel in diesem Heft
- Reviews
- The STANISLAS Cohort: a 10-year follow-up of supposed healthy families. Gene-environment interactions, reference values and evaluation of biomarkers in prevention of cardiovascular diseases
- Cardiovascular biomarkers: increasing impact of laboratory medicine in cardiology practice
- Haemolysis: an overview of the leading cause of unsuitable specimens in clinical laboratories
- Cardiovascular Diseases
- APOA5 Ala315>Val, identified in patients with severe hypertriglyceridemia, is a common mutation with no major effects on plasma lipid levels
- Gender-modulated impact of apolipoprotein A5 gene (APOA5) −1131T>C and c.56C>G polymorphisms on lipids, dyslipidemia and metabolic syndrome in Turkish adults
- Oxidative stress markers, C-reactive protein and heat shock protein 70 levels in subjects with metabolic syndrome
- Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing
- Distribution of plasma cardiac troponin I values in healthy subjects: pathophysiological considerations
- High-density lipoprotein cholesterol and paraoxonase 1 (PON1) genetics and serum PON1 activity in prepubertal children in Spain
- Genetics and Molecular Diagnostics
- Polymorphisms of CYP17A1, CYP19, and androgen in Brazilian women with uterine leiomyomas
- A novel MEN1 frameshift germline mutation in two Italian monozygotic twins
- The silent hemoglobin α chain variant Hb Riccarton [α51(CE9)Gly→Ser] may affect HbA1c determination on the HLC-723 G7 analyzer
- General Clinical Chemistry and Laboratory Medicine
- Urinary fructose-1,6-bisphosphatase activity as a marker of the damage to the renal proximal tubules in children with idiopathic nephrotic syndrome
- Antioxidant defense capacity in scleroderma patients
- Correction of ventricular cerebrospinal fluid (CSF) samples for blood content does not increase sensitivity and specificity for the detection of CSF infection
- Validation and Outcome Studies
- Preanalytical quality control program – an overview of results (2001–2005 summary)
- A laboratory-based risk score for medical intensive care patients
- Analytical performance evaluation of the Cobas 6000 analyzer – special emphasis on trueness verification
- Letters to the Editor
- Quality planning and analytical quality requirements derived from biology
- Importance of sample size in hospital point-of-care glucose measurements
- Reliability of M protein quantification: comparison of two peak integration methods on Capillarys 2
- What's in a name? Standardization of HbA1c
- Serum paraoxonase 1 activities and homocysteinemia in hemodialysis patients
